Shop Now Contact

Anti-Human CTLA-4 (Tremelimumab Biosimilar)

Cat # Size Price Quantity
5064011 mg$175
5064025 mg$550
50640320 mg$1100

  Bulk/Custom

Product Details

CloneTremelimumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionTremelimumab Biosimilar, Human CTLA-4 monoclonal Antibody
IsotypeHuman IgG2
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman CTLA-4
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsCD152
RRIDAB_3739339
Target NameCTLA4, CD152, CELIAC3, GSE, IDDM12
Antibody TypeRecombinant
Research AreasTregs, Activated T cells, Autoimmunity, Immune Checkpoints, Cancer Immunology
See All FormatsClone Tremelimumab

Background Information

Tremelimumab is a fully human monoclonal antibody belonging to the immunoglobulin G2 (IgG2) subclass, designed to specifically bind to cytotoxic T-lymphocyte–associated protein 4 (CTLA-4, also known as CD152). Structurally, it is a glycoprotein with an approximate molecular weight of 147 kilodaltons (kDa). The molecule consists of two identical heavy chains and two identical light chains joined by interchain disulfide bonds, forming the classic Y-shaped IgG configuration. Each heavy chain includes one variable (VH) and three constant (CH1-CH3) domains, while each light chain comprises one variable (VL) and one constant (CL) domain. Tremelimumab is produced in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, ensuring correct folding, assembly, and human-like glycosylation.

The complementarity-determining regions (CDRs) within Tremelimumab’s variable domains define its high-affinity and specific recognition of an epitope on the extracellular portion of CTLA-4. CTLA-4 is an immune checkpoint receptor expressed on activated T cells and regulatory T cells, functioning as an inhibitory regulator of T-cell signaling. Tremelimumab binds to CTLA-4 with nanomolar affinity through a network of hydrogen bonds and hydrophobic interactions, preventing CTLA-4 from engaging its natural ligands, CD80 (B7-1) and CD86 (B7-2), on antigen-presenting cells. By blocking this interaction, the antibody inhibits the suppressive signaling pathways normally mediated by CTLA-4, thereby facilitating the co-stimulatory interaction between CD28 and B7 molecules in experimental immunological systems. This results in enhanced T-cell activation and proliferation through the modulation of intracellular kinases and transcriptional regulators such as ZAP-70 and NFAT.

The Fc (fragment crystallizable) region of Tremelimumab, characteristic of the IgG2 subclass, provides structural integrity and contributes to a long systemic half-life through neonatal Fc receptor (FcRn) recycling. Compared with IgG1 antibodies, the IgG2 isotype exhibits reduced complement activation and limited antibody-dependent cellular cytotoxicity (ADCC). Overall, Tremelimumab represents a rationally engineered human IgG2 monoclonal antibody optimized for high-affinity checkpoint receptor blockade, structural stability, and defined modulation of T-cell–mediated immune responses in mechanistic studies of immune regulation.

Data Sheets

Anti-Human CTLA-4 (Tremelimumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Anti-Human CD80 (Galiximab Biosimilar), Clone Galiximab

Human B7-1 (CD80) Protein (C-His-Avi)

Biotin Human B7-1 (CD80) Protein (C-His-Avi)

Human B7-1 (CD80) Protein (C-His)

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.